Table 4.
Various Studies Done on Post–COVID-19 FGID/DGBI
| Study | No. of patients/controls | Frequency of IBS/FGIDs in cases | Frequency of IBS/FGIDs in controls | Follow-up (mo) | Comments |
|---|---|---|---|---|---|
| Ghoshal et al19 (2021) | 280/264 | IBS: 5.3% UD: 2.1% IBS-UD overlap: 1.8% |
IBS: 0.3% | 6 | Historical controls No investigations done for MAS |
| Velez et al20 (2022) | 200/no controls | IBS: 29% FD: 1% Overlap: 9.5% |
— | 6 | No controls |
| Blackett et al21 (2022) | 1783/no controls | GI symptoms: 29% | — | 6 | No controls |
| Ziyad Al-Aly et al3 (2021) | 33,940 breakthrough infections vs controls | Increased GI disturbances | — | 6 | Self-reported questionnaire No investigations done for MAS |
| Oshima et al22 (2020) | 5157/no controls | FD: 8.5% IBS: 16.6% FD-IBS: 4% |
— | 6 | No controls |
| Nakov et al23 (2021) | 1896/980 | FGID: 36% | 6 | Controls not well-defined No investigations done for MAS |
|
| Noviello et al24 (2021) | 164/183 | IBS: 26.2% | IBS: 25.1% | 5 | Controls not well-defined No investigations done for MAS |
FD, functional dyspepsia; FGID, functional gastrointestinal disorders; GI, gastrointestinal; IBS, irritable bowel syndrome; MAS, malabsorption syndrome; UD, uninvestigated dyspepsia.